-
FDA Places Cara Therapeutics' Pain Trial On Clinical Hold, Shares Plunge 42%
Friday, February 26, 2016 - 8:35am | 237Cara Therapeutics Inc (NASDAQ: CARA), a clinical-stage bio-pharmaceutical company that focuses on the development of chemical entities to alleviate pain and pruritus, announced a business update after Thursday's market close. Cara Therapeutics said that the U.S. Food and Drug Administration has...